Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study

Bibliographic Details
Title: Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
Authors: Renfang Yang, Tao Wu, Jiehai Yu, Xinyi Cai, Guoyu Li, Xiangshu Li, Weixin Huang, Ya Zhang, Yuqin Wang, Xudong Yang, Yongping Ren, Ruixi Hu, Qing Feng, Peirong Ding, Xuan Zhang, Yunfeng Li
Source: Frontiers in Immunology, Vol 14 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: locally advanced rectal cancer, neoadjuvant immunotherapy, programmed cell death protein-1 inhibitor, mismatch repair-deficient, clinical complete response, watch-and-wait strategy, Immunologic diseases. Allergy, RC581-607
More Details: ObjectiveExamine patients with locally advanced rectal cancer (LARC) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant immunotherapy (nIT), and compare the outcomes of those who chose a watch-and-wait (WW) approach after achieving clinical complete response (cCR) or near-cCR with those who underwent surgery and were confirmed as pathological complete response (pCR).MethodsLARC patients with dMMR/MSI-H who received nIT were retrospectively examined. The endpoints were 2-year overall survival (OS), 2-year disease-free survival (DFS), local recurrence (LR), and distant metastasis (DM). The efficacy of programmed cell death protein-1 (PD-1) inhibitor, immune-related adverse events (irAEs), surgery-related adverse events (srAEs), and enterostomy were also recorded.ResultsTwenty patients who received a PD-1 inhibitor as initial nIT were examined. Eighteen patients (90%) achieved complete response (CR) after a median of 7 nIT cycles, including 11 with pCR after surgery (pCR group), and 7 chose a WW strategy after evaluation as cCR or near-cCR (WW group). Both groups had median follow-up times of 25.0 months. Neither group had a case of LR or DM, and the 2-year DFS and OS in each group was 100%. The two groups had similar incidences of irAEs (P=0.627). In the pCR group, however, 2 patients (18.2%) had permanent colostomy, 3 (27.3%) had temporary ileostomy, and 2 (18.2%) had srAEs.ConclusionNeoadjuvant PD-1 blockade had high efficacy and led to a high rate of CR in LARC patients with dMMR/MSI-H. A WW strategy appears to be a safe and reliable option for these patients who achieve cCR or near-cCR after nIT.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1182299/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2023.1182299
Access URL: https://doaj.org/article/ca95d77b7a84446a924f15f1bacb0330
Accession Number: edsdoj.95d77b7a84446a924f15f1bacb0330
Database: Directory of Open Access Journals
More Details
ISSN:16643224
DOI:10.3389/fimmu.2023.1182299
Published in:Frontiers in Immunology
Language:English